Gland Pharma Appoints Deepak Sapra as New Chief Executive Officer

HYDERABAD, India — Gland Pharma Limited announced on Friday, August 14, 2026, that its Board of Directors has approved the appointment of Deepak Sapra as the company’s new Chief Executive Officer (CEO). The executive leadership change will take effect on November 16, 2026, subject to formal acceptance of the offer.

The decision follows recommendations from the company’s Nomination and Remuneration Committee and was disclosed in regulatory filings to Indian stock exchanges. The appointment brings a veteran pharmaceutical leader to head the Hyderabad-headquartered generic injectables manufacturer.

Strategic Executive Leadership Transition

Gland Pharma Limited confirmed the appointment of Deepak Sapra as Chief Executive Officer in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The incoming Chief Executive Officer brings 27 years of overall executive experience, including more than 23 years within the global pharmaceutical sector. He currently serves as the Chief Executive Officer for Active Pharmaceutical Ingredients (API) and Services at Dr. Reddy’s Laboratories Limited, while also holding a board position at Aurigene Pharma Services.

At Dr. Reddy's Laboratories, Sapra leads an integrated business-to-business (B2B) organization spanning active pharmaceutical ingredients, generic pharmaceuticals, custom development and manufacturing organization (CDMO) services, global alliances, and public health access programs. His operational leadership extends across key markets including the United States, European Union, Japan, China, Brazil, Mexico, the Middle East, and Africa.

Executive Background and Industry Experience

Deepak Sapra’s professional background encompasses the pharmaceutical value chain, including CDMO partnerships, API development, business expansion, regulatory portfolio strategy, and global supply chain management.

Prior to his role leading API and Services, Sapra served as Chief Executive Officer for Custom Pharmaceutical Services, where he managed CDMO relationships serving innovator pharmaceutical companies across North America, Europe, and Japan. Between 2011 and 2015, he held senior positions including Vice President of Global Generics Business Development and Senior Director of Global Generics Portfolio Management.

Academic qualifications for the incoming CEO include a Bachelor’s degree in Mechanical Engineering from the Indian Railways Institute of Mechanical and Electrical Engineering (IRIMEE) in Jamalpur, alongside a Master’s degree in Management from the Indian Institute of Management (IIM) Bangalore. He was also awarded a Chevening Scholarship at the University of Bradford in the United Kingdom and a Fulbright Fellowship at Carnegie Mellon University in Pittsburgh, United States.

Official Sources Section

Gland Pharma Limited released details of the appointment through official corporate filings signed by Company Secretary and Compliance Officer Sampath Kumar Pallerlamudi. The filings were submitted to BSE Limited (Scrip Code: 543245) and the National Stock Exchange of India Limited (Symbol: GLAND).

The disclosures comply with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Gland Pharma confirmed there are no inter-director family relationships relevant to this board appointment.

Quote Section

According to official filings submitted by the corporate compliance division, board approvals followed formal committee evaluations.

"In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Deepak Sapra, as the new Chief Executive Officer (CEO) of the Company," stated Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer of Gland Pharma Limited.

Why It Matters

The executive transition comes at a critical juncture for Gland Pharma Limited as generic injectable manufacturers face complex regulatory landscapes and shifting global supply chain dynamics.

Sapra’s extensive experience in global CDMO partnerships, API integration, and portfolio expansion across regulated markets—such as the U.S., Europe, and Japan—provides strategic continuity. For equity investors and industry stakeholders, his track record in business development and M&A offers leadership stability for Gland Pharma's international strategy.

Key Facts at a Glance

• New Leadership: Deepak Sapra appointed as Chief Executive Officer of Gland Pharma Limited.

• Effective Date: The CEO appointment becomes effective on November 16, 2026.

• Current Executive Role: Sapra currently serves as CEO of API and Services at Dr. Reddy’s Laboratories.

• Domain Focus: Brings 23+ years of pharmaceutical experience spanning APIs, CDMO services, and global generics.

• Regulatory Filing: Corporate update submitted to BSE and NSE under SEBI Regulation 30.

Frequently Asked Questions (FAQ)

Who has been appointed as the new CEO of Gland Pharma?

Deepak Sapra has been appointed as the Chief Executive Officer of Gland Pharma Limited.

When will Deepak Sapra assume the CEO role at Gland Pharma?

Deepak Sapra will formally join Gland Pharma Limited as Chief Executive Officer with effect from November 16, 2026.

What is Deepak Sapra's current professional role?

He currently serves as Chief Executive Officer – API and Services at Dr. Reddy’s Laboratories Limited and as a Board Member of Aurigene Pharma Services.

What educational background does the incoming CEO hold?

Deepak Sapra holds a Mechanical Engineering degree from IRIMEE, Jamalpur, a Master's degree in Management from IIM Bangalore, and completed Chevening and Fulbright fellowships in the UK and US.

Source: BSE Limited Direct Exchange Filing Desk, National Stock Exchange of India Limited Listing Portal, and Gland Pharma Limited Official Investor Relations Disclosures.